The gut-brain axis and GLP-1 production GLP-1 (glucagon-like peptide-1) is produced primarily by L-cells in your small intestine and colon
Combination protocols carry added complexity and risk
These wider impacts are every bit as significant as weight loss proper, influencing both health in general and daily life
But what happens when you stop taking them
Based on other injectable medicines in this class, Retatrutide is expected to require refrigeration at 2C to 8C, kept in its original packaging, and out of sight and reach of children
When dose reduction is appropriate Phase 3 trials include provisions for dose reduction: Gastrointestinal adverse events or inadequate oral intake may warrant stepping down to a lower dose level see Retatrutide Side Effects for incidence rates by dose BMI reaching 22 kg/m or below , or perceived excessive weight loss, allows dose reduction Treatment is discontinued at BMI 18.5 kg/m or below How Often and When to Take Retatrutide Injection frequency once weekly by subcutaneous injection, on the same day each week
